Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development

Core Insights - Immunome, Inc. is focusing on building an oncology pipeline centered on cell-surface-targeting agents and small molecules [1][2] - The company aims to develop a targeted oncology platform that can overcome resistance and enable bystander activity, with a market opportunity of $1 billion targeting over 3,000 patients treated annually [2][3] - Immunome plans to submit three additional Investigational New Drug (IND) applications this year for solid tumor programs, alongside the FDA clearance for its radioligand therapy [3][4] Company Overview - Immunome, Inc. is a clinical-stage biotechnology company that specializes in discovering and developing first-in-class targeted therapies for oncology, primarily utilizing antibody-drug conjugate (ADC) technology [4] - The company employs a proprietary memory B cell-based discovery engine to identify novel antibodies for cancer treatment [4]